Advantar Laboratories, Inc, San Diego, CA 92121, USA.
Eye Contact Lens. 2013 Jul;39(4):295-302. doi: 10.1097/ICL.0b013e3182973d5c.
To determine the equilibrium binding constant (EB) values of bimatoprost and tafluprost drug product formulations in contact with lotrafilcon A soft contact lenses and to characterize the importance of drug molecule hydrophobicity in controlling the binding interactions.
Bimatoprost Ophthalmic Solution and Tafluprost Ophthalmic Solution (Saflutan) were incubated with lotrafilcon A lens material for timed intervals at 25°C and 37°C. Aliquots were withdrawn, filtered, and tested using reverse-phase ultrahigh-performance liquid chromatography with respect to [bimatoprost] or [tafluprost] remaining in the solution. A series of homologous dialkyl phthalate esters and a series of homologous p-hydroxybenzoic acid alkyl esters were also tested as reference compounds.
Bimatoprost and tafluprost were rapidly (within 15 min) absorbed from the solution by lotrafilcon A lenses, reaching an equilibrium within 60 min. At any lens:solution (w/v) ratio, the extent of drug binding to lens material was greater for tafluprost than for bimatoprost. The log(EB) values correlated with solute octanol:water partition coefficient (logP) values, indicating that hydrophobic interactions are important in controlling solute partitioning into the lens material.
This study established the quantitative relationships between tafluprost and bimatoprost binding to lotrafilcon A lenses. The fraction of bimatoprost or tafluprost that binds to lotrafilcon A increases with increasing lens:solution (w/v) ratio. For a 60 µL dose volume applied to a single contact lens, 16% of initially present bimatoprost remains in the solution, whereas only 6% of initially present tafluprost remains in the solution. These calculations clearly demonstrate that both drugs partition extensively into lotrafilcon A contact lens material. Although the clinical implications of such binding can only be surmised, it would seem prudent to caution contact lens wearers to remove the lenses before administering either prostaglandin drug.
确定比马前列素和他氟前列素药物制剂与 lotrafilcon A 软性隐形眼镜接触时的平衡结合常数（EB）值，并研究药物分子疏水性在控制结合相互作用中的重要性。
将比马前列素滴眼液和他氟前列素滴眼液（Saflutan）在 25°C 和 37°C 下与 lotrafilcon A 镜片材料孵育一段时间。在溶液中取出等分试样，过滤，并使用反相超高效液相色谱法测试剩余的[比马前列素]或[他氟前列素]。还测试了一系列同系二烷基邻苯二甲酸酯和一系列同系对羟基苯甲酸烷基酯作为参考化合物。
比马前列素和他氟前列素从溶液中被 lotrafilcon A 镜片迅速（在 15 分钟内）吸收，在 60 分钟内达到平衡。在任何镜片：溶液（w/v）比下，药物与镜片材料的结合程度对于他氟前列素比对马前列素更高。log(EB)值与溶质辛醇：水分配系数（logP）值相关，表明疏水相互作用对于控制溶质分配到镜片材料中很重要。
本研究建立了他氟前列素和比马前列素与 lotrafilcon A 镜片结合的定量关系。与 lotrafilcon A 镜片结合的比马前列素或他氟前列素比例随镜片：溶液（w/v）比的增加而增加。对于应用于单个隐形眼镜的 60 µL 剂量体积，初始存在的比马前列素中有 16%留在溶液中，而初始存在的他氟前列素中只有 6%留在溶液中。这些计算清楚地表明，两种药物都广泛分配到 lotrafilcon A 隐形眼镜材料中。尽管这种结合的临床意义只能推测，但似乎谨慎的做法是告诫隐形眼镜佩戴者在施用任何前列腺素药物之前先取下镜片。
